Research programme: microbiome therapeutics - SNIPR Biome
Latest Information Update: 28 Apr 2023
At a glance
- Originator SNIPR Biome
- Class Antineoplastics; Bacteria; Gene therapies
- Mechanism of Action Bacteria replacements; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer